Miscellaneous
The U.S. Food and Drug Administration faces a costly and consequential decision over whether to approve a controversial new Alzheimer’s drug.Guest:Caleb Alexander, Professor of Epidemiology and Medicine, Johns Hopkins Bloomberg School of Public HealthView the transcript for today's episode: https://tradeoffs.org/2021/06/03/the-fdas-pressure-packed-alzheimers-drug-decisionTake our short listener survey, and you could win a $50 gift card! bit.ly/TradeoffsSurveySign up for our weekly newsletter to see what research health policy experts are reading right now, plus recommendations from our staff: bit.ly/tradeoffsnewsletterSupport this type of journalism today, with a gift: https://tradeoffs.org/donateFollow us on Twitter: https://twitter.com/tradeoffspod See acast.com/privacy for privacy and opt-out information.